DrAndrew Marshall
Scientist
Ferrier Research Institute
Orcid identifier0000-0003-0022-2001 (opens in a new tab)
- ScientistFerrier Research Institute
- +6444630045 (Work)
BIO
Dr Andrew Marshall joined Professor Gavin Painter’s Chemical Immunology team at the Ferrier Research Institute in late 2016, to provide small molecular drug discovery experience for the development of new immunotherapies. Dr Marshall received his PhD in molecular medicine in 2011 from the University of Auckland.
He was also member of the Pathway Therapeutics drug discovery programme spun out of the Auckland Cancer Society Research Centre to develop promising PI3K inhibitors as anticancer agents. From this work a dual PI3K/mTOR inhibitor (PWT33597) was discovered, and underwent Phase 1 clinical trial in 2011).
Andrew continued at the ACSRC as a Research Fellow where he contributed to anti- cancer drug discovery programmes including the designed and synthesised novel radiosensitizers for the treatment of solid tumour, stealth prodrugs targeting FGFR driven non-small cell lung cancer (a follow on programme for TH-4000, which underwent Phase 2 clinical trial in 2015). He was also a member of a collaborative team with the Drugs for Neglected disease initiative that discovered DNDI-0690, which is currently undergoing preclinical development for the treatment of visceral leishmaniasis.
Andrew is excited to have joined the collaborative vaccine development programme between the Ferrier Research Institute and Malaghan Institute of Medical Research
He was also member of the Pathway Therapeutics drug discovery programme spun out of the Auckland Cancer Society Research Centre to develop promising PI3K inhibitors as anticancer agents. From this work a dual PI3K/mTOR inhibitor (PWT33597) was discovered, and underwent Phase 1 clinical trial in 2011).
Andrew continued at the ACSRC as a Research Fellow where he contributed to anti- cancer drug discovery programmes including the designed and synthesised novel radiosensitizers for the treatment of solid tumour, stealth prodrugs targeting FGFR driven non-small cell lung cancer (a follow on programme for TH-4000, which underwent Phase 2 clinical trial in 2015). He was also a member of a collaborative team with the Drugs for Neglected disease initiative that discovered DNDI-0690, which is currently undergoing preclinical development for the treatment of visceral leishmaniasis.
Andrew is excited to have joined the collaborative vaccine development programme between the Ferrier Research Institute and Malaghan Institute of Medical Research